Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Completed · Phase 4 · NCT04718870
Conditions: Dermatitis Atopic
At a glance
- Research payments reported, 2025
- $4,482
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 41
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab SAR231893 (drug)
- Dates
- Started 2021-02-19; completion 2022-11-30
- Results posted
- Yes
Primary Objective: \- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic dermatitis (AD) treated with dupilumab. Secondary Objectives: * Evaluate changes in skin barrier function with TEWL assessed after STS in predefined lesional and non-lesional skin in pediatric participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers. * Evaluate time course of change in skin barrier function with TEWL assessed before and after STS in predefined lesional and non-lesional skin in pediatric partic…
From ClinicalTrials.gov, last updated 2025-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $4,482 in research payments for this study in 2025 (3 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.